Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 8, 2024
Advantages and Challenges of Total-Body PET/CT at a Tertiary Cancer Center: Insights from Sun Yat-sen University Cancer CenterWanqi Chen, Yinghe Li, Zhijian Li, et al.
Translational Psychiatry|November 1, 2025
Brain metabolic vulnerability in 18-F FDG PET/CT predict future depression risk in young cancer survivorsNianqi Liu, Jingjie Sun, Yongluo Jiang, et al.
Science China. Life Sciences|January 10, 2024
The burgeoning importance of PIWI-interacting RNAs in cancer progressionXinpei Deng, Tianle Liao, Jindong Xie, et al.
European Radiology|February 15, 2024
Learning CT-free attenuation-corrected total-body PET images through deep learningWenbo Li, Zhenxing Huang, Zixiang Chen, et al.
Frontiers in Immunology|June 14, 2023
Continuation of anti-PD-1 therapy plus physician-choice treatment beyond first progression is not associated with clinical benefit in patients with advanced non-small cell lung cancerYixing Wang, Sha Fu, Xuanye Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|June 4, 2021
Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1/PD-L1 monotherapyLi-Na He, Sha Fu, Xuanye Zhang, et al.
Frontiers in Bioengineering and Biotechnology|October 24, 2022
Dynamic alteration in SULmax predicts early pathological tumor response and short-term prognosis in non-small cell lung cancer treated with neoadjuvant immunochemotherapyTaotao Sun, Shujie Huang, Yongluo Jiang, et al.
Thoracic Cancer|April 19, 2022
A CT-based radiomics model to predict subsequent brain metastasis in patients with ALK-rearranged non-small cell lung cancer undergoing crizotinib treatmentYongluo Jiang, Yixing Wang, Sha Fu, et al.
Lung Cancer (Amsterdam, Netherlands)|January 20, 2022
Reducing number of target lesions for RECIST1.1 to predict survivals in patients with advanced non-small-cell lung cancer undergoing anti-PD1/PD-L1 monotherapyLi-Na He, Tao Chen, Sha Fu, et al.
Therapeutic Advances in Medical Oncology|October 26, 2023
Tumor response assessment by measuring the single largest lesion per organ in advanced non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitorLi-Na He, Tao Chen, Sha Fu, et al.
Pageof 3